Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Rudà R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC. Hoang-Xuan K, et al. Among authors: ferreri ajm. Neuro Oncol. 2023 Jan 5;25(1):37-53. doi: 10.1093/neuonc/noac196. Neuro Oncol. 2023. PMID: 35953526 Free PMC article.
Primary central nervous system lymphoma.
Ferreri AJ, Reni M. Ferreri AJ, et al. Crit Rev Oncol Hematol. 2007 Sep;63(3):257-68. doi: 10.1016/j.critrevonc.2007.04.012. Epub 2007 Jun 21. Crit Rev Oncol Hematol. 2007. PMID: 17590348 Review.
Whole-brain radiotherapy in primary CNS lymphoma.
Ferreri AJ, DeAngelis L, Illerhaus G, O'Neill BP, Reni M, Soussain C, Yahalom J. Ferreri AJ, et al. Lancet Oncol. 2011 Feb;12(2):118-9; author reply 119-20. doi: 10.1016/S1470-2045(11)70018-3. Lancet Oncol. 2011. PMID: 21277546 No abstract available.
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.
Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, DeAngelis LM. Deckert M, et al. Leukemia. 2011 Dec;25(12):1797-807. doi: 10.1038/leu.2011.169. Epub 2011 Aug 5. Leukemia. 2011. PMID: 21818113 Review.
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M. Kasenda B, et al. Ann Oncol. 2015 Jul;26(7):1305-13. doi: 10.1093/annonc/mdv076. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701456 Free PMC article. Review.
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Hoang-Xuan K, et al. Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Lancet Oncol. 2015. PMID: 26149884 Free article. Review.
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G. Schorb E, et al. BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4. BMC Cancer. 2016. PMID: 27098429 Free PMC article. Clinical Trial.
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
387 results